Impaired fasting glucose and impaired glucose tolerance: Implications for care

Diabetes Care

Volumn 30, Issue 3, 2007, Pages 753-759

  Nathan, David M ^a   Davidson, Mayer B ^b   DeFronzo, Ralph A ^c   Heine, Robert J ^d   Henry, Robert R ^e   Pratley, Richard ^f   Zinman, Bernard ^g   Kahn, Richard ^h  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^f UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^g UNIVERSITY OF TORONTO   (Canada)

^h AMERICAN DIABETES ASSOCIATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE;

CARDIOVASCULAR RISK; CONFERENCE PAPER; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEALTH BEHAVIOR; HEALTH STATUS; HUMAN; IMPAIRED FASTING GLUCOSE; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PHYSICAL ACTIVITY; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; WEIGHT REDUCTION;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FASTING; GLUCOSE INTOLERANCE; PREVALENCE; UNITED STATES;

EID: 33847645068     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc07-9920     Document Type: Conference Paper

References (59)

1. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, Marks JS: Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289:76-79, 2003
2. CDC: National Diabetes Fact Sheet, 2005. Available from http://www.cdc.gov/diabetes/pubs/factsheet05.htm. Accessed 4 December 2006
3. International Diabetes Federation: Diabetes Atlas. Available from http://www.eatlas.idf.org. Accessed 4 December 2006
4. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusituupa M, the Finnish Diabetes Prevention Study group: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
5. Knowler WC, Barrett-Conner E, Fowler SE, Hammon RF, Lachin JM, Walker EA, Nathan DM, the Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
6. Vendrame F, Gottlieb PA: Prediabetes: prediction and prevention trials. Endocrinol Metab Clin North Am 33:75-92, 2004
7. Larson H, Lindgarde F, Berglund G, Ahren B: Prediction of diabetes using ADA or WHO criteria in post-menopausal women: a 10-year follow-up study. Diabetologia 43:1224-1228, 2004
8. Santaguida PL, Balion C, Hunt D, Morrison K, Gerstein H, Raina P, Booker L, Yazdi H: Diagnosis, prognosis, and treatment of impaired glucose tolerance and impaired fasting glucose. AHRQ Study 128:1-12, 2006
9. Shaw JE, Zimmet PZ, de Courten M, Dowse GK, Chitson P, Gareeboo H, Hemraj F, Fareed D, Tuomilehto J, Alberti KG: Impaired fasting glucose or impaired glucose tolerance: what best predicts future diabetes in Mauritius? Diabetes Care 22:399-402, 1999
10. DeVegt F, Dekker JM, Jager A, Hienkens E, Kostense PJ, Stehouwer CD, Nijpets G, Bouter LM, Heine RJ: Relations of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch populations: the Hoorn Study. JAMA 285:2109-2113, 2001
11. Coutinho M, Gerstein HC, Wang Y, Yusuf S: The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22:233-240, 1999
12. Levitan EB, Song Y, Ford ES, Liu S: Is non-diabetic hyperglycemia a risk factor for cardiovascular disease? A meta-analysis of prospective studies. Arch Intern Med 164:2147-2155, 2004
13. DECODE Study Group, on behalf of the European Diabetes Epidemiology Group: Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161:397-405, 2001
14. DECODE Study Group, on behalf of the European Diabetes Epidemiology Group: Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 26:688-696, 2003
15. Barzilay JI, Spiekerman CF, Wahl PW, Kuller LH, Cushman M, Furgerg CD, Dobs A, Polak JF, Savage PJ: Cardiovascular disease in older adults with glucose disorders: comparison of American Diabetes Association criteria for diabetes mellitus with WHO criteria. Lancet 354:622-625, 1999
16. Saydoh SH, Miret M, Sung J, Varas C, Gause D, Brancati FL: Post-challenge hyperglycemia and mortality in a national sample of U.S. adults. Diabetes Care 24:1397-1402, 2001
17. Balkau B, Hu G, Qiao Q, Tuomilehto J, Borch-Johnsen K, Pyorala K, DECODE Study Group, European Diabetes Epidemiology Group: Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor: the DECODE Study. Diabetologia 47:2118-2128, 2004
18. Balkau B, Forhan A, Eschawege E: Two hour plasma glucose is not unequivocally predictive for early death in men with impaired fasting glucose: more results from the Paris Prospective Study. Diabetologia 45:1224-1230, 2002
19. Stern MP, Fatehi P, Williams K, Haffner SM: Predicting future cardiovascular disease: do we need the oral glucose tolerance test? Diabetes Care 25:1851-1856, 2002
20. Gabir MM, Hanson RL, Dabetea D, Imperatore G, Roumain J, Bennett PH, Knowler WC: Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes. Diabetes Care 23:1113-1118, 2002
21. Meigs JB, Nathan DM, D'Agostino RB Sr, William PW: Fasting and post-challenge glycemia and cardiovascular disease risk: the Framingham Offspring Study. Diabetes Care 25:1845-1850, 2002
22. Tominaga M, Equchi H, Manaka H, Igarashi K, Kato T, Sekikawa A: Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose: the Funagata Diabetes Study. Diabetes Care 22:920-924, 1999
23. Chiasson JL, Josse RG, Gomis R, Hanefetd M, Karasik A, Laakso M, the STOP-NIDDM Trial Research Group: Acarbose for prevention of type 2 diabetes metlitus: the STOP-NIDDM randomized trial. Lancet 359:2072-2077, 2002
24. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijav V: Indian Diabetes Prevention Programme (IDPP): the Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prervent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49:289-297, 2006
25. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroguin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis HN, Azzen SP: Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 51:2796-2803, 2002
26. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, AN ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 20:537-544, 1997
27. Gerstein HC, Yusuf S, Boxch J, Pogue J, Sheridan P, Dinccag N, Hanefetd M, Hoogwerf B, Laaskso M, Mohan V, Shaw J, Zinman B, Holman RR: DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trial Investigators: effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 368:1096-1105, 2006
28. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L: Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27:151-161, 2004
29. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Hahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, Nathan D, Palmer J, Rizza R, Saudek C, Shaw J, Steffes M, Stern M, Tuomilehto J, Zimmet P: Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160-3167, 2003
30. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-1197, 1997
31. De Vegt F, Dekker JM, Stehower CD, Nijpets G, Bouter LM, Heine RJ: The 1997 American Diabetes Association criteria versus the 1985 World Health Organization criteria for the diagnosis of abnormal glucose tolerance: poor agreement in the Hoorn Study. Diabetes Care 21:1680-1690, 1998
32. Dunstan DW, Zimmet PZ, Welborn TA, De Courten MP, Cameron AJ, Sicree RA, Owyer T, Colagiuri S, Jolley D, Knuiman M, Atkins R, Shaw JE: The rising prevalence of diabetes and impaired glucose tolerance: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 25:829-834, 2002
33. Ko GT, Chan JC, Woo J, Cockram CS: Use of the 1997 American Diabetes Association diagnostic criteria for diabetes in a Hong Kong Chinese population. Diabetes Care 21:2094-2097, 1998
34. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, Saydah SH, Williams DE, Geiss LS, Gregg EW: Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999-2002. Diabetes Care 29:1263-1268, 2006
35. Qiao Q, Nakagami T, Tuomilehto J, Borch-Johnsen K, Balkau B, Iwamoto Y, Tajima N, International Diabetes Epidemiology Group, DECODA Study Group: Comparison of the fasting and the 2-h glucose criteria for diabetes in different Asian cohorts. Diabetologia 43:1470-1475, 2000
36. Nakagami T, Qiao Q, Tuomilehto J, Balkau B, Carstensen B, Tajimia N, Iwamoto Y, Borch-Johnsen K, DECODA Study Group, Diabetes Epidemiology Collaborative Analysis of Diagnostic Criteria in Asia, International Diabetes Epidemiology Group: The fasting plasma glucose cut-point predicting a diabetic 2-h OGTT glucose level depends on the phenotype. Diabetes Res Clin Pract 55:35-43, 2002
37. Gabir MM, Hanson RL, Dabetea D, Imperatore G, Roumain J, Bennett PH, Knowler WC: The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 23:1108-1112, 2000
38. Stern MP, Williams K, Haffner SM: Identification of persons at high risk for type 2 diabetes mellitus: do we need the oral glucose tolerance test? Ann Intern Med 136:575-581, 2002
39. Kahn SE: The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 46:3-19, 2003
40. College of American Pathologist: Participant Summary. College of American Pathologists, Northfield, IL, 2005
41. Moog JM, Grootenhuis PA, De Vries H, Kostense PJ, Popp-Snijders C, Bouter LM, Heine RJ: Intra-individual variation of glucose, specific insulin and pro-insulin concentrations measured by two oral glucose tolerance tests in a general Caucasian population: the Hoorn Study. Diabetologia 39:298-305, 1996
42. Ko GT, Chan JC, Woo J, Lau E, Yeung VT, Chow CC, Cockram CS: The reproducibility and usefulness of the oral glucose tolerance test in screening for diabetes and other cardiovascular risk factors. Ann Clin Biochem 35:62-67, 1998
43. Brohall G, Behre CJ, Wikstrand J, Fagerberg B: Prevalence of diabetes and impaired glucose tolerance in 64-year-old Swedish women: experiences of using repeated oral glucose tolerance tests. Diabetes Care 29:363-367, 2006
44. Weyer C, Bogardus C, Pratley RE: Metabolic characteristics of individuals with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 48:2197-2203, 1999
45. Davies MJ, Raymond NT, Day JL, Hales CN, Burden AC: Impaired glucose tolerance and fasting hyperglycaemia have different characteristics. Diabet Med 17:433-440, 2000
46. Hetdgaard PE, Olivarius Nde F, Hindsberger C, Henriksen JE: Impaired fasting glycaemia resembles impaired glucose tolerance with regard to cardiovascular risk factors: population-based, cross-sectional study of risk factors for cardiovascular disease. Diabet Med 21:363-370, 2004
47. Blake DR, Meigs JB, Muller DC, Najjar SS, Andres R, Nathan DM: Impaired glucose tolerance, but not impaired fasting glucose, is associated with increased levels of coronary heart disease risk factors: results from the Baltimore Longitudinal Study on Aging. Diabetes 53:2095-2100, 2004
48. Lim S, Tai ES, Tan BY, Chew SK, Tan CE: Cardiovascular risk profile in individuals with borderline glycemia: the effect of the 1997 American Diabetes Association diagnostic criteria and the 1998 World Health Organization Provisional Report. Diabetes Care 23:278-282, 2000
49. Novoa FJ, Boronat M, Saavedra P, Diaz-Cremades JM, Varillas VF, La Roche F, Alberiche MP, Carrillo A: Differences in cardiovascular risk factors, insulin resistance, and insulin secretion in individuals with normal glucose tolerance and in subjects with impaired glucose regulation: the Telde Study. Diabetes Care 28:2388-2393, 2005
50. Rijkelijkhuizen JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CDA, Dekker JM: High risk of cardiovascular mortality in individuals with impaired fasting glucose is explained by conversion to diabetes: The Hoorn Study. Diabetes Care 30:332-336, 2007
51. Qiao Q, Jousilahti P, Eriksson J, Tuomilehto J: Predictive properties of impaired glucose tolerance for cardiovascular risk are not explained by the development of overt diabetes during follow-up. Diabetes Care 26:2910-2914, 2003
52. Abdul-Ghani MA, Jenkinson CP, Richardson DK, Tripathy D, DeFronzo RA: Insulin secretion and action in subjects with impaired fasting glucose and impaired glucose tolerance: results from the Veterans Administration Genetic Epidemiology Study. Diabetes 55:1430-1435, 2006
53. Hanefeld M, Koehler C, Fuechker K, Henket E, Schaper F, Temetkova-Kurktschiev T: Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the Risk Factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes Study. Diabetes Care 26:868-874, 2003
54. Abdul-Ghani MA, Tripathy D, DeFronzo RA: Contributions of β-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care 29:1130-1139, 2006
55. Festa A, D'Agostino R Jr, Hanley AJ, Karter AJ, Saad MF, Hafner SM: Differences in insulin resistance in nondiabetic subjects with isolated impaired glucose tolerance or isolated impaired fasting glucose. Diabetes 53:1549-1555, 2004
56. Knowler WC, Hamman RF, Edelstein SL, Barrett-Conner E, Ehrmann DA, Walker EA, Fowler SE, Nathan DM, Kahn SE, the DPP Research Group: Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 54:1150-1156, 2005
57. Chisson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, the STOP-NIDDM Trial Research Group: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 290:486-494, 2003
58. Ratner R, Goldberg R, Haffner S, Marcovina S, Orchard T, Fowler S, Temprosa M, the DPP Research Group: Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care 28:888-894, 2005
59. American Diabetes Association: Standards of medical care in diabetes - 2006. Diabetes Care 29 (Suppl. 1):S4-S42, 2006